14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 26, 2024

Conditions
Helicobacter PyloriDrug Resistance, Multiple
Interventions
DRUG

Bismuth-based susceptibility-guided treatment

The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.

Trial Locations (1)

704302

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

Ministry of Health and Welfare, Taiwan

OTHER_GOV

lead

National Cheng-Kung University Hospital

OTHER